Letter to the editor for the article “Does the urinary microbiome profile change after treatment of bladder cancer?”

Excerpt

We were interested to read the impressive study by Hussein et al. in World Journal of Urology [1] and would like to congratulate the authors for their excellent study about urinary microbiome during bladder cancer (BCa) treatment. Hussein et al. [1] systematically compared the urinary microbiome profile between “Tumor group” (de novo tumors or recurrent/progressed after transurethral resection of BCa ± intravesical therapy) and “No Recurrent Tumor group” (no evidence of recurrence after treatment) based on 16S rRNA sequencing from 68 BCa urine samples. The authors [1] found beta diversity of microbiome was significantly different between the two groups (P = 0.04), which indicated the dynamic change during treatment. In addition, “Tumor group” carried more Veillonella and Bifidobacterium (P < 0.001), while Escherichia-Shigella and Helococcus were more abundant in “No Recurrent Tumor group” (P < 0.001). This research provides valuable insights into clinical management of BCa. However, there are a few points that we would like to discuss. …